{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,9,9]],"date-time":"2024-09-09T14:16:15Z","timestamp":1725891375794},"publisher-location":"Berlin, Heidelberg","reference-count":77,"publisher":"Springer Berlin Heidelberg","isbn-type":[{"type":"print","value":"9783642780127"},{"type":"electronic","value":"9783642780103"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[1993]]},"DOI":"10.1007\/978-3-642-78010-3_20","type":"book-chapter","created":{"date-parts":[[2012,7,28]],"date-time":"2012-07-28T23:39:01Z","timestamp":1343518741000},"page":"212-229","source":"Crossref","is-referenced-by-count":1,"title":["Psychotropic Drug Metabolism and Clinical Monitoring"],"prefix":"10.1007","author":[{"given":"A. E.","family":"Balant-Gorgia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L. P.","family":"Balant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"20_CR1","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/978-3-642-74430-3_30","volume-title":"Clinical Pharmacology in Psychiatry","author":"AC Altamura","year":"1989","unstructured":"Altamura AC, Mauri M, Cavallaro R, Regazzetti MG, Bareggi SR (1989) Hydroxyhaloperidol and clinical outcome in schizophrenia. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer Berlin Heidelberg New York, pp 263\u2013268 (Psychopharmacology series 7 )"},{"key":"20_CR2","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1007\/978-1-349-06671-1_15","volume-title":"Clinical Pharmacology in Psychiatry","author":"R Axelsson","year":"1983","unstructured":"Axelsson R, M\u00e5rtensson E (1983) Clinical effects related to the serum concentrations of thioridazine and its metabolites. In: Gram LF, Usdin E, Dahl SG, Krag-S\u00f8rensen P, Sj\u00f6qvist F, Morselli PL (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 165\u2013174"},{"key":"20_CR3","doi-asserted-by":"publisher","first-page":"65","DOI":"10.2165\/00003088-198713020-00001","volume":"13","author":"AE Balant-Gorgia","year":"1987","unstructured":"Balant-Gorgia AE, Balant LP (1987) Antipsychotic drugs: Clinical pharmacokinetics of potential candidates for plasma concentration monitoring. Clin Pharmacokinet 13: 65\u201390","journal-title":"Clin Pharmacokinet"},{"key":"20_CR4","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/BF00613523","volume":"31","author":"AE Balant-Gorgia","year":"1986","unstructured":"Balant-Gorgia AE, Balant LP, Genet C, Dayer P, Aeschlimann JM, Garrone G (1986) Importance of oxidative polymorphism and levomepromazine treatment on the steady-state blood concentrations of clomipramine and its major metabolites. Eur J Clin Pharmacol 31: 449\u2013455","journal-title":"Eur J Clin Pharmacol"},{"key":"20_CR5","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1007\/BF03189886","volume":"12","author":"AE Balant-Gorgia","year":"1987","unstructured":"Balant-Gorgia AE, Balant LP, Gex-Fabry M, Genet C (1987) Stereoselective disposition of flupentixol: influence on steady-state plasma concentrations in schizophrenic patients. Eur J Drug Metab Pharmacokinet 12: 123\u2013128","journal-title":"Eur J Drug Metab Pharmacokinet"},{"key":"20_CR6","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/00007691-198911040-00008","volume":"11","author":"AE Balant-Gorgia","year":"1989","unstructured":"Balant-Gorgia AE, Balant LP, Garrone G (1989) High blood concentrations of imipramine or clomipramine and therapeutic failure: a case report study using drug monitoring data. Ther Drug Monit 11: 415\u2013420","journal-title":"Ther Drug Monit"},{"key":"20_CR7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1007\/978-1-349-06671-1_20","volume-title":"Clinical Pharmacology in Psychiatry","author":"L Bertilsson","year":"1983","unstructured":"Bertilsson L, Mellstr\u00f6m B, Nordin C, Siwers B, Sj\u00f6qvist F (1983) Stereospecific 10- hydroxylation of nortriptyline: genetic aspects and importance for biochemical and clinical effects. In: Gram LF, Usdin E, Dahl SG, Krag-S\u00f8rensen P, Sj\u00f6qvist F, Morselli PL (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 217\u2013226"},{"key":"20_CR8","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1038\/clpt.1986.173","volume":"40","author":"L Bertilsson","year":"1986","unstructured":"Bertilsson L, Nordin C, Otani K, Resul B, Scheinin M, Siwers B, Sj\u00f6qvist F (1986) Disposition of single oral doses of E-10-hydroxynortriptyline in healthy subjects, with some observations on pharmacodynamic effects. Clin Pharmacol Ther 40: 261\u2013267","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR9","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/978-3-642-74430-3_6","volume-title":"Clinical Pharmacology in Psychiatry","author":"L Bertilsson","year":"1989","unstructured":"Bertilsson L, Dahl-Puustinen ML, Nordin C (1989) E-10-hydroxynortriptyline: effects and disposition of a potential novel antidepressant. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 52\u201359 (Psychopharmacology series 7 )"},{"key":"20_CR10","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1038\/clpt.1982.85","volume":"31","author":"JL Bock","year":"1982","unstructured":"Bock JL, Giller E, Gray S, Jatlow P (1982) Steady-state plasma concentrations of cis- and trans-10-OH-amitriptyline metabolites. Clin Pharmacol Ther 31: 609\u2013616","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR11","first-page":"139","volume":"4","author":"AD Broadhurst","year":"1977","unstructured":"Broadhurst AD, James HD, Delia Corte L, Heeley AF (1977) Clomipramine plasma level and clinical response. Postgrad Med J 53 Suppl 4: 139\u2013145","journal-title":"Postgrad Med J 53 Suppl"},{"key":"20_CR12","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1007\/BF00614194","volume":"30","author":"K Br\u00f8sen","year":"1986","unstructured":"Br\u00f8sen K, Gram LF, Klysner R, Bech P (1986) Steady-state levels of imipramine and its metabolites: significance of dose-dependent kinetics. Eur J Clin Pharmacol 30: 43\u201349","journal-title":"Eur J Clin Pharmacol"},{"key":"20_CR13","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1080\/01971528508063020","volume":"6","author":"JL Browning","year":"1985","unstructured":"Browning JL, Harrington CA, Davis CM (1985) Quantification of reduced haloperidol and haloperidol by radioimmunoassay. J Immunoassay 6: 45\u201366","journal-title":"J Immunoassay"},{"key":"20_CR14","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1002\/cpt1979255part1605","volume":"25","author":"DJ Brunswick","year":"1979","unstructured":"Brunswick DJ, Amsterdam JD, Mendels J, Stern SL (1979) Prediction of steady-state imipramine and desmethylimipramine plasma concentrations from single-dose data. Clin Pharmacol Ther 25: 605\u2013610","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR15","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/BF00609423","volume":"37","author":"BS Chakraborty","year":"1989","unstructured":"Chakraborty BS, Hubbard JW, Hawes EM, McKay G, Cooper JK, Gurnsey T, Korchinsky ED, Midha KK (1989) Interconversion between haloperidol and reduced haloperidol in healthy volunteers. Eur J Clin Pharmacol 37: 45\u201348","journal-title":"Eur J Clin Pharmacol"},{"key":"20_CR16","doi-asserted-by":"publisher","first-page":"1406","DOI":"10.1016\/0006-3223(87)90074-6","volume":"22","author":"WH Chang","year":"1987","unstructured":"Chang WH, Chen TY, Lee CF, Hu WH, Yeh EK (1987) Low plasma reduced haloperido\/haloperidol ratios in Chinese patients. Biol Psychiatry 22: 1406\u20131408","journal-title":"Biol Psychiatry"},{"key":"20_CR17","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1097\/00004714-199104000-00005","volume":"11","author":"WH Chang","year":"1991","unstructured":"Chang WH, Lin SK, Jann MW (1991) Interconversion between haloperidol and reduced haloperidol in schizophrenic patients and guinea pigs: a steady-state study. J Clin Psychopharmacol 11: 99\u2013105","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR18","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1007\/978-1-349-05929-4_10","volume-title":"Clinical Pharmacology in Psychiatry","author":"SG Dahl","year":"1981","unstructured":"Dahl SG (1981) Active metabolites of phenothiazine drugs. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 125\u2013137"},{"key":"20_CR19","first-page":"33","volume-title":"Raven, New York","author":"SG Dahl","year":"1982","unstructured":"Dahl SG (1982) Actives metabolites of neuroleptic drugs: possible contribution to therapeutic and toxic effects. In: Raven, New York 4: 33\u201340"},{"key":"20_CR20","doi-asserted-by":"publisher","first-page":"36","DOI":"10.2165\/00003088-198611010-00003","volume":"11","author":"SG Dahl","year":"1986","unstructured":"Dahl SG (1986) Plasma level monitoring of antipsychotic drugs clinical utility. Clin Pharmacol 11: 36\u201361","journal-title":"Clin Pharmacol"},{"key":"20_CR21","volume-title":"Psychiatry: a world perspective","author":"SG Dahl","year":"1990","unstructured":"Dahl SG (1990) Conditions for meaningful plasma level monitoring of neuroleptics. In: Stefanis CN, Rabavilas AD, Soldatos CR (eds) Psychiatry: a world perspective, vol 3. Excerpta Medica, Amsterdam"},{"key":"20_CR22","first-page":"409","volume":"21","author":"SG Dahl","year":"1981","unstructured":"Dahl SG, Hjorth M, Hough E (1981) Chlorpromazine, metrotrimeprazine, and metabolites. Structural changes accompanying the loss of neuroleptic potency by ring sulfoxidation. Mol Pharmacol 21: 409\u2013414","journal-title":"Mol Pharmacol"},{"key":"20_CR23","first-page":"136","volume-title":"Clinical Pharmacology in Psychiatry","author":"SG Dahl","year":"1982","unstructured":"Dahl SG, Hals PA, Johnsen H, Morel E, Lloyd KG (1982) Possible role of hydroxymetabolites in the action of neuroleptics. In: Gram LF, Usdin E, Dahl SG Krag-S\u00f8rensen P, Sjoqvist F, Morselli PL (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 136\u2013149"},{"key":"20_CR24","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1038\/clpt.1989.86","volume":"45","author":"ML Dahl-Puustinen","year":"1989","unstructured":"Dahl-Puustinen ML, Perry TL, Dumont E, von Bahr C, Nordin C, Bertilsson L (1989) Stereoselective disposition of racemin E-10-hydroxynortriptyline in human beings. Chn Pharmacol Ther 45: 650\u2013656","journal-title":"Chn Pharmacol Ther"},{"key":"20_CR25","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1192\/bjp.134.4.390","volume":"134","author":"L Corte Della","year":"1979","unstructured":"Della Corte L, Broadhurst AD, Sgaragli GP, Filippini S, Heeley AF, Faravelli C, Pazzagli A (1979) Clinical response and tricyclic plasma levels during treatment with clomipramine. Br J Psychiatry 134: 390\u2013400","journal-title":"Br J Psychiatry"},{"key":"20_CR26","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/0165-0327(84)90011-9","volume":"6","author":"C Faravelli","year":"1984","unstructured":"Faravelli C, Ballerini A, Ambonetti A, Broadhurst AD, Das M (1984) Plasma levels and clinical response during treatment with clomipramine. J Affect Dis 6: 95\u2013107","journal-title":"J Affect Dis"},{"key":"20_CR27","doi-asserted-by":"publisher","first-page":"396","DOI":"10.2165\/00003088-198917060-00004","volume":"17","author":"JS Froemming","year":"1989","unstructured":"Froemming JS, Francis Lam YW, Jann MW, Davis CM (1989) Pharmacokinetics of haloperidol. Clin Pharmacokinet 17: 396\u2013423","journal-title":"Clin Pharmacokinet"},{"key":"20_CR28","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00004714-198908000-00007","volume":"9","author":"DL Garver","year":"1989","unstructured":"Garver DL (1989) Neuroleptic drug levels and antipsychotic effects: a difficult correlation; potential advantage of free (or derivative) versus total plasma levels. J Clin Psychopharmacol 9: 277\u2013281","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR29","doi-asserted-by":"publisher","first-page":"241","DOI":"10.2165\/00003088-199019030-00007","volume":"19","author":"M Gex-Fabry","year":"1990","unstructured":"Gex-Fabry M, Balant-Gorgia A, Balant LP, Garrone G (1990) Clomipramine metabolism: model-based analysis of variability factors from drug monitoring data. Clin Pharmacokinet 19: 241\u2013255","journal-title":"Clin Pharmacokinet"},{"key":"20_CR30","first-page":"1323","volume-title":"Psychopharmacology: the third generation of progress","author":"S Guthrie","year":"1987","unstructured":"Guthrie S, Lane EA, Linnoila M (1987) Monitoring of plasma drug concentrations in clinical psychopharmacology. In: Mellzer HY (ed) Psychopharmacology: the third generation of progress. Raven, New York, pp 1323\u20131338"},{"key":"20_CR31","first-page":"430P","volume":"57","author":"RB Jones","year":"1976","unstructured":"Jones RB, Luscombe DK (1976) Plasma levels of clomipramine and its N-desmethyl metabolite following oral administration of clomipramine in man. Br J Pharmacol 57: 430 P","journal-title":"Br J Pharmacol"},{"key":"20_CR32","first-page":"111","volume":"9","author":"A J\u00f8rgensen","year":"1986","unstructured":"J\u00f8rgensen A (1986) Metabolism and pharmacokinetics of antipsychotic drugs. Prog Drug Metab 9: 111\u2013174","journal-title":"Prog Drug Metab"},{"key":"20_CR33","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1097\/00004714-198906000-00005","volume":"9","author":"GN Ko","year":"1989","unstructured":"Ko GN, Korpi ER, Kirch DG (1989) Haloperidol and reduced haloperidol concentrations in plasma and red blood cells from chronic schizophrenic patients. J Clin Psychopharmacol 9: 186\u2013190","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR34","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1176\/ajp.140.4.490","volume":"140","author":"KM Lin","year":"1983","unstructured":"Lin KM, Finder E (1983) Neuroleptic dosage for Asians. Am J Psychiatry 140: 490\u2013491","journal-title":"Am J Psychiatry"},{"key":"20_CR35","doi-asserted-by":"publisher","first-page":"208","DOI":"10.1038\/clpt.1982.149","volume":"32","author":"M Linnoila","year":"1982","unstructured":"Linnoila M, Insel T, Kilts C, Potter WZ, Murphy DL (1982) Plasma steady-state concentrations of hydroxylated metabolites of clomipramine. Clin Pharmacol Ther 32: 208\u2013211","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR36","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1097\/00007691-199011000-00011","volume":"12","author":"T Loennechen","year":"1990","unstructured":"Loennechen T, Andersen A, Hals PA, Dahl SG (1990) High-performance liquid chromatographic determination of levomepromazine (metrotrimeprazine) and its mains metabolites in serum and urine. Ther Drug Monit 12: 574\u2013581","journal-title":"Ther Drug Monit"},{"key":"20_CR37","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1097\/00007691-199101000-00010","volume":"13","author":"MJ Lovdahl","year":"1991","unstructured":"Lovdahl MJ, Perry PJ, Miller DD (1991) The assay of clozapine and N- Desmethylclozapine in human plasma by high-performance liquid chromatography. Ther Drug Monit 13: 69\u201372","journal-title":"Ther Drug Monit"},{"key":"20_CR38","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1365-2125.1974.tb00281.x","volume":"1","author":"AVP Mackay","year":"1974","unstructured":"Mackay AVP, Heeley AF, Baker J (1974) The relationship of plasma chlorpromazine to its 7-hydroxy and sulphoxide metabolites in a large population of chronic schizophrenics. Br J Clin Pharmacol 1: 425\u2013430","journal-title":"Br J Clin Pharmacol"},{"key":"20_CR39","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1007\/978-3-642-74430-3_31","volume-title":"Clinical Pharmacology in Psychiatry","author":"SR Marder","year":"1989","unstructured":"Marder SR, Van Putten T, Aravagiri M (1989a) Plasma level monitoring for maintenance neuroleptic therapy. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 269\u2013279 (Psychopharmacology series 7 )"},{"key":"20_CR40","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1007\/BF00441937","volume":"98","author":"SR Marder","year":"1989","unstructured":"Marder SR, Hubbard JW, Van Putten T, Midha KK (1989b) Pharmacokinetics of long-acting injectable neuroleptic drugs: Clinical implications. Psychopharmacology (Berl) 98: 433\u2013439","journal-title":"Psychopharmacology (Berl)"},{"key":"20_CR41","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/978-3-642-74430-3_29","volume-title":"Clinical Pharmacology in Psychiatry","author":"E M\u00e5rtensson","year":"1989","unstructured":"M\u00e5rtensson E, Nyberg G (1989) Active metabolites of neuroleptics in plasma and CSF: Implications for therapeutic drug monitoring. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer Berlin Heidelberg New York, pp 257\u2013262 (Psychopharmacology series 7)"},{"key":"20_CR42","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1038\/clpt.1981.147","volume":"30","author":"B Mellstr\u00f6m","year":"1981","unstructured":"Mellstr\u00f6m B, Bertilsson L, S\u00e4we J, Schulz HU, Sj\u00f6qvist F (1981) E- and Z-10- hydroxylation of nortriptyline: relationship to polymorphic debrisoquine hydroxylation. Clin Pharmacol Ther 30: 189\u2013193","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR43","doi-asserted-by":"publisher","first-page":"358","DOI":"10.1097\/00007691-198709000-00018","volume":"9","author":"KK Midha","year":"1987","unstructured":"Midha KK, Hubbard JW, Cooper JK, Gurnsey T, Hawes EM, McKay G, Chakraborty BS, Yeung PKF (1987a) Therapeutic monitoring of chlorpromazine IV: comparison of a new high-performance liquid chromatographic method with radioimmunoassays for parent drug and some of its major metabolites. Ther Drug Monit 9: 358\u2013365","journal-title":"Ther Drug Monit"},{"key":"20_CR44","doi-asserted-by":"publisher","first-page":"369","DOI":"10.1007\/BF00187259","volume":"93","author":"KK Midha","year":"1987","unstructured":"Midha KK, Hubbard JW, Marder SR, Hawes EM, Van Putten T, McKay G, May PRA (1987b) The sulfoxidation of fluphenazine in schizophrenic patients maintained on fluphenazine decanoate. Psychopharmacology (Berl) 93: 369\u2013373","journal-title":"Psychopharmacology (Berl)"},{"key":"20_CR45","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1097\/00007691-198802000-00011","volume":"10","author":"KK Midha","year":"1988","unstructured":"Midha KK, Cooper JK, Hawes EM, Hubbard JW, Korchinski ED, McKay G (1988) An ultrasensitive method for measurement of haloperidol and reduced haloperidol in plasma by high-performance liquid chromatography with coulometric detection. Ther Drug Monit 10: 177\u2013183","journal-title":"Ther Drug Monit"},{"key":"20_CR46","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1097\/00004714-198904000-00005","volume":"9","author":"KK Midha","year":"1989","unstructured":"Midha KK, Chakraborty BS, Ganes DA, Hawes EM, Hubbard JW, Keegan DL, Korchinski ED, McKay G (1989) Intersubject variation in the pharmacokinetics of haloperidol and reduced haloperidol. J Clin Psychopharmacol 9: 98\u2013104","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR47","doi-asserted-by":"publisher","first-page":"129","DOI":"10.2165\/00003088-197904020-00005","volume":"4","author":"SA Montgomery","year":"1979","unstructured":"Montgomery SA, McAuley R, Montgomery DB, Braithwaite RA, Dawling S (1979) Dosage adjustment from simple nortriptyline spot level predictor tests in depressed patients. Clin Pharmacokinet 4: 129\u2013136","journal-title":"Clin Pharmacokinet"},{"key":"20_CR48","first-page":"130","volume":"1","author":"SA Montgomery","year":"1980","unstructured":"Montgomery SA, McAuley R, Montgomery DB, Dawling S, Braithwaite RA (1980) Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. Postgrad Med J 56 Suppl 1: 130\u2013133","journal-title":"Postgrad Med J 56 Suppl"},{"key":"20_CR49","doi-asserted-by":"crossref","first-page":"S71","DOI":"10.1097\/00002826-199001001-00008","volume":"1","author":"SA Montgomery","year":"1990","unstructured":"Montgomery SA, Baldwin D, Shah A, Fineberg N, Montgomery D (1990) Plasma-level response with fluoxetine and zimelidine. Clin Neuropharmacol 13 Suppl 1: S71\u2013S75","journal-title":"Clin Neuropharmacol 13 Suppl"},{"key":"20_CR50","first-page":"127","volume":"1","author":"ICA Moyes","year":"1980","unstructured":"Moyes ICA, Ray RL, Moyes RB (1980) Plasma levels and clinical improvement: a comparative study of clomipramine and amitriptyline in depression. Postgrad Med J 56 Suppl 1: 127\u2013129","journal-title":"Postgrad Med J 56 Suppl"},{"key":"20_CR51","doi-asserted-by":"publisher","first-page":"666","DOI":"10.1038\/clpt.1987.93","volume":"6","author":"JC Nelson","year":"1987","unstructured":"Nelson JC, Jatlow PI (1987) Nonlinear desipramine kinetics: prevalence and importance. Clin Pharmacol Ther 6: 666\u2013670","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR52","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1038\/clpt.1983.28","volume":"33","author":"JC Nelson","year":"1983","unstructured":"Nelson JC, Bock JL, Jatlow PI (1983) Clinical implications of 2-hydroxydesipramine plasma concentrations. Clin Pharmacol Ther 33: 183\u2013189","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR53","first-page":"72","volume":"7","author":"JC Nelson","year":"1987","unstructured":"Nelson JC, Jatlow PI, Mazure C (1987) Rapid desipramine dose adjustment using 24-hour levels. Clin Psychopharmacol 7: 72\u201377","journal-title":"Clin Psychopharmacol"},{"key":"20_CR54","doi-asserted-by":"publisher","first-page":"283","DOI":"10.1038\/clpt.1988.151","volume":"44","author":"JC Nelson","year":"1988","unstructured":"Nelson JC, Mazure C, Jatlow PI (1988a) Antidepressant activity of 2-hydroxydesipramine. Clin Pharmacol Ther 44: 283\u2013288","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR55","doi-asserted-by":"publisher","first-page":"428","DOI":"10.1097\/00004714-198812000-00009","volume":"8","author":"JC Nelson","year":"1988","unstructured":"Nelson JC, Atillasoy E, Mazure C, Jatlow PI (1988b) Hydroxydesipramine in the elderly. J Clin Psychopharmacol 8: 428\u2013433","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR56","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/978-3-642-74430-3_24","volume-title":"Clinical Pharmacology in Psychiatry","author":"JC Nelson","year":"1989","unstructured":"Nelson JC, Mazure C, Jatlow PI (1989) Clinical implications of the pharmacokinetics of tricyclic antidepressants. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 219\u2013227 (Psychopharmacology series 7 )"},{"key":"20_CR57","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/clpt.1987.101","volume":"42","author":"C Nordin","year":"1987","unstructured":"Nordin C, Bertilsson L, Siwers B (1987) Clinical and biochemical effects during treatment of depression with nortriptyline: the role of 10-hydroxynortriptyline. Clin Pharmacol Ther 42: 10\u201319","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR58","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1007\/978-3-642-74430-3_26","volume-title":"Clinical Pharmacology in Psychiatry","author":"BG Pollock","year":"1989","unstructured":"Pollock BG, Perel JM (1989) Hydroxy metabolites of tricyclic antidepressants: evaluation of relative cardiotoxicity. In: Dahl SG, Gram LF (eds) Clinical pharmacology in psychiatry. Springer, Berlin Heidelberg New York, pp 232\u2013236 (Psychopharmacology series 7 )"},{"key":"20_CR59","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/0165-1781(84)90017-9","volume":"12","author":"DG Potkin","year":"1984","unstructured":"Potkin DG, Shen YC, Pardes H, Phelps BH, Zhou DF, Shu L, Korpi ER, Wyatt RJ (1984) Haloperidol concentration elevated in Chinese patients. Psychiatry Res 12: 167\u2013172","journal-title":"Psychiatry Res"},{"key":"20_CR60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/978-1-349-05929-4_11","volume-title":"Clinical Pharmacology in Psychiatry","author":"WZ Potter","year":"1981","unstructured":"Potter WZ (1981) Active metabolites of tricyclic antidepressants. In: Usdin E, Dahl SG, Gram LF, Lingjaerde O (eds) Clinical pharmacology in psychiatry. Macmillan, London, pp 139\u2013153"},{"key":"20_CR61","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1038\/clpt.1982.50","volume":"31","author":"WZ Potter","year":"1982","unstructured":"Potter WZ, Calil HM, Sutfin TA, Zavadil AP, Jusko WJ, Rapoport J, Goodwin FK (1982) Active metabolites of imipramine and desipramine. Clin Pharmacol Ther 31: 393\u2013401","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR62","first-page":"341","volume":"3","author":"N Reisby","year":"1979","unstructured":"Reisby N, Gram LF, Bech P, Sihm F, Krautwald O, Elley J, Christiansen J (1979) Clomipramine: plasma levels and clinical effects. Commun Psychopharmacol 3: 341\u2013351","journal-title":"Commun Psychopharmacol"},{"key":"20_CR63","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1097\/00004714-198708000-00003","volume":"7","author":"JG Rigal","year":"1987","unstructured":"Rigal JG, Albin HC, Duchier AR, D\u2019Aulnay JM, Fenelon JH, Vincon GA, Demotes-Mainard FM (1987) Imipramine blood levels and clinical outcome. J Clin Psychopharmacol 7: 222\u2013229","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR64","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1097\/00004714-198812000-00004","volume":"8","author":"LS Schneider","year":"1988","unstructured":"Schneider LS, Cooper TB, Severson JA, Zemplenyi T, Sloane RB (1988) Electrocardiographic changes with nortriptyline and 10-hydroxynortriptyline in elderly depressed outpatients. J Clin Psychopharmacol 8: 402\u2013408","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR65","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1097\/00004714-199010000-00005","volume":"10","author":"LS Schneider","year":"1990","unstructured":"Schneider LS, Cooper TB, Suckow RF, Lyness SA, Haugen C, Palmer R, Sloane RB (1990) Relationship of hydroxy nortriptyline to nortriptyline concentration and creatinine clearance in depressed elderly outpatients. J Clin Psychopharmacol 10: 333\u2013337","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR66","doi-asserted-by":"publisher","first-page":"394","DOI":"10.1097\/00004714-198712000-00004","volume":"7","author":"M Shostak","year":"1987","unstructured":"Shostak M, Perel JM, Stiller RL, Wyman W, Curran S (1987) Plasma haloperidol and clinical response. A role for reduced haloperidol in antipsychotic activity? J Clin Psychopharmacol 7: 394\u2013400","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR67","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/00007691-199009000-00007","volume":"12","author":"SH Sindrup","year":"1990","unstructured":"Sindrup SH, Br\u00f8sen K, Gram LF (1990) Nonlinear kinetics of imipramine in low and medium plasma level ranges. Ther Drug Monit 12: 445\u2013449","journal-title":"Ther Drug Monit"},{"key":"20_CR68","doi-asserted-by":"publisher","first-page":"377","DOI":"10.2165\/00003088-198005040-00005","volume":"5","author":"JT Slattery","year":"1980","unstructured":"Slattery JT, Gibaldi M, Koup JR (1980) Prediction of maintenance dose required to attain a desired drug concentration at steady-state from a single determination of concentration after an initial dose. Clin Pharmacokinet 5: 377\u2013385","journal-title":"Clin Pharmacokinet"},{"key":"20_CR69","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1016\/0165-1781(90)90114-K","volume":"31","author":"T Someya","year":"1990","unstructured":"Someya T, Takahashi S, Shibasaki M, Inaba T, Cheung SW, Tang SW (1990) Reduced haloperidol\/haloperidol ratios in plasma: polymorphism in Japanese psychiatric patients. Psychiatry Res 31: 111\u2013120","journal-title":"Psychiatry Res"},{"key":"20_CR70","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1097\/00004714-199104000-00004","volume":"11","author":"SL Stern","year":"1991","unstructured":"Stern SL, Ribner HS, Cooper TB, Nelson LD, Johnson MH, Suckow RF (1991) 2-Hydroxydesipramine and desipramine plasma levels and electrocardiographic effects in depressed younger adults. J Clin Psychopharmacol 11:93\u201398","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR71","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/00004714-198802000-00009","volume":"8","author":"TA Sutfin","year":"1988","unstructured":"Sutfin TA, Perini GI, Molnar G, Jusko WJ (1988) Multiple-dose pharmacokinetics of imipramine and its major active and conjugated metabolites in depressed patients. J Clin Psychopharmacol 8: 48\u201353","journal-title":"J Clin Psychopharmacol"},{"key":"20_CR72","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/BF00606419","volume":"22","author":"B Vandel","year":"1982","unstructured":"Vandel B, Vandel S, Jounet JM, Allers G, Volmat R (1982) Relationship between the plasma concentration of clomipramine and desmethylclomipramine in depressive patients and the clinical response. Eur J Clin Pharmacol 22: 15\u201320","journal-title":"Eur J Clin Pharmacol"},{"key":"20_CR73","first-page":"595","volume":"37","author":"S Vandel","year":"1989","unstructured":"Vandel S, Bertschy G, Vandel B, Allers G, Volmat R (1989) Amitriptyline: linear or nonlinear kinetics in every day practice? Eur J Pharmacol 37: 595\u2013598","journal-title":"Eur J Pharmacol"},{"key":"20_CR74","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1007\/BF02657069","volume":"39","author":"S Vandel","year":"1990","unstructured":"Vandel S, Bertschy G, Allers G, Volmat R (1990) Nonlinear Kinetics of nortriptyline in every day practice. Eur J Clin Pharmacol 39: 97\u201398","journal-title":"Eur J Clin Pharmacol"},{"key":"20_CR75","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/clpt.1991.22","volume":"49","author":"C Bahr Von","year":"1991","unstructured":"Von Bahr C, Movin G, Nordin C, Lid\u00e9n A, Hammarlund-Udenaes M, Hedberg A, Ring H, Sj\u00f6qvist F (1991) Plasma levels of thioridazine and metabolites are influenced by the debrisoquin hydroxylation phenotype. Clin Pharmacol Ther 49: 234\u2013240","journal-title":"Clin Pharmacol Ther"},{"key":"20_CR76","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1007\/BF00431102","volume":"73","author":"B Wode-Helgodt","year":"1981","unstructured":"Wode-Helgodt B, Alfredsson G (1981) Concentrations of chlorpromazine and two of its active metabolites in plasma and cerebrospinal fluid of psychotic patients treated with fixed drug doses. Psychopharmacology (Berl) 73: 55\u201362","journal-title":"Psychopharmacology (Berl)"},{"key":"20_CR77","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1097\/00007691-198802000-00008","volume":"10","author":"RC Young","year":"1988","unstructured":"Young RC, Dhar AK, Kutt H, Alexopoulos GS (1988) Isomers of 10-hydroxynortriptyline in geriatric depression. Ther Drug Monit 10: 164\u2013167","journal-title":"Ther Drug Monit"}],"container-title":["Clinical Pharmacology in Psychiatry"],"original-title":[],"link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/978-3-642-78010-3_20.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,27]],"date-time":"2024-04-27T19:17:33Z","timestamp":1714245453000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/978-3-642-78010-3_20"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1993]]},"ISBN":["9783642780127","9783642780103"],"references-count":77,"URL":"https:\/\/doi.org\/10.1007\/978-3-642-78010-3_20","relation":{},"subject":[],"published":{"date-parts":[[1993]]}}}